Could Moleculin Biotech Incorporated (NASDAQ:MBRX) Go Down After Its Newest Short Interest Report?

February 15, 2018 - By Louis Casey

 Could Moleculin Biotech Incorporated (NASDAQ:MBRX) Go Down After Its Newest Short Interest Report?

The stock of Moleculin Biotech Incorporated (NASDAQ:MBRX) registered a decrease of 2.65% in short interest. MBRX’s total short interest was 1.39M shares in February as published by FINRA. Its down 2.65% from 1.43 million shares, reported previously. With 158,600 shares average volume, it will take short sellers 9 days to cover their MBRX’s short positions. The short interest to Moleculin Biotech Incorporated’s float is 16.38%.

The stock increased 58.25% or $1.0601 during the last trading session, reaching $2.8801. About 29.48M shares traded or 8745.63% up from the average. Moleculin Biotech, Inc. (NASDAQ:MBRX) has 0.00% since February 15, 2017 and is . It has underperformed by 16.70% the S&P500.

Moleculin Biotech, Inc., a preclinical-stage pharmaceutical company, focuses on the development of anti-cancer drug candidates. The company has market cap of $60.87 million. The Company’s lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia. It currently has negative earnings. The firm also develops other drugs, including WP1066 Portfolio that focuses on the modulation of regulatory transcription factors involved in the progression of cancer; and WP1122 Portfolio, a suite of molecules targeting the metabolic processes involved in cancer and glioblastoma.

More notable recent Moleculin Biotech, Inc. (NASDAQ:MBRX) news were published by: which released: “Moleculin Biotech (MBRX) Reports FDA Approval of Annamycin IND” on September 26, 2017, also with their article: “Moleculin Biotech’s stock rockets after ‘major breakthrough’ in cancer treatment” published on February 15, 2018, published: “Moleculin announces “major breakthrough” in cancer treatment; shares up 54%” on February 15, 2018. More interesting news about Moleculin Biotech, Inc. (NASDAQ:MBRX) were released by: and their article: “Moleculin Biotech (MBRX) Shows Promising Tumor Suppression Activity with …” published on February 07, 2018 as well as‘s news article titled: “Moleculin Biotech (MBRX) Reports Significant Discovery with Potential to Treat …” with publication date: June 21, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.